Please try another search
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Karen Jean Ferrante | 65 | 2018 | Independent Director |
Todd E. Shegog | 57 | 2021 | Independent Director |
Christopher W. Cain | 39 | 2020 | Independent Director |
Arlene M. Morris | 71 | 2019 | Independent Director |
Kwok-Kin Wong | - | - | Member of Scientific Advisory Board |
Srdan Verstovsek | - | - | Member of Scientific Advisory Board |
Matthew E. Ros | 56 | 2019 | Independent Director |
Andrew R. Robbins | 47 | 2020 | President, CEO & Director |
Ryan B. Corcoran | - | - | Member of Scientific Advisory Board |
Peter Evan Harwin | 37 | 2020 | Independent Chairman of the Board |
Michael J. Vasconcelles | 59 | - | Member of Scientific Advisory Board |
Sylvia Adams | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review